L R Whitfield - JoVE Visualize

Showing results (21-30 of 33) with videos related to

Pageof 4

Sort By:

Cancer Research|October 1, 1989

Development of a radioimmunoassay for the anthrapyrazole chemotherapy agent CI-937 and the pharmacokinetics of CI-937 in ratsG D Nordblom, L A Pachla, T Chang, et al.

Clinical Pharmacology and Therapeutics|December 1, 1996

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjectsD D Cilla, L R Whitfield, D M Gibson, et al.

Journal of Clinical Pharmacology|October 1, 1995

Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitorL L Radulovic, D D Cilla, E L Posvar, et al.

Journal of Clinical Pharmacology|August 1, 1996

Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjectsE L Posvar, L L Radulovic, D D Cilla, et al.

Cancer Research|December 1, 1991

Phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole, CI-937 (DUP937)C Erlichman, M Moore, I G Kerr, et al.

Therapeutic Drug Monitoring|March 5, 1998

Development, validation, and interlaboratory comparison of an HMG-CoA reductase inhibition assay for quantitation of atorvastatin in plasma matricesY Y Shum, N Huang, G Walter, et al.

Pharmacotherapy|May 1, 1997

Pharmacometric analysis of the effect of furosemide on suramin pharmacokineticsS C Piscitelli, A Forrest, R M Lush, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000

A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumorsE C Dees, L R Whitfield, W R Grove, et al.

Journal of Clinical Pharmacology|March 1, 1996

Effect of age and gender on pharmacokinetics of atorvastatin in humansD M Gibson, N J Bron, A Richens, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1992

A high-performance liquid chromatographic assay for CI-973, a new anticancer platinum diamine complex, in human plasma and urine ultrafiltratesW W Bullen, L D Andress, T Chang, et al.

Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:

Pageof 4

Cancer Research|October 1, 1989

Development of a radioimmunoassay for the anthrapyrazole chemotherapy agent CI-937 and the pharmacokinetics of CI-937 in ratsG D Nordblom, L A Pachla, T Chang, et al.

Clinical Pharmacology and Therapeutics|December 1, 1996

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjectsD D Cilla, L R Whitfield, D M Gibson, et al.

Journal of Clinical Pharmacology|October 1, 1995

Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitorL L Radulovic, D D Cilla, E L Posvar, et al.

Journal of Clinical Pharmacology|August 1, 1996

Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjectsE L Posvar, L L Radulovic, D D Cilla, et al.

Cancer Research|December 1, 1991

Phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole, CI-937 (DUP937)C Erlichman, M Moore, I G Kerr, et al.

Therapeutic Drug Monitoring|March 5, 1998

Development, validation, and interlaboratory comparison of an HMG-CoA reductase inhibition assay for quantitation of atorvastatin in plasma matricesY Y Shum, N Huang, G Walter, et al.

Pharmacotherapy|May 1, 1997

Pharmacometric analysis of the effect of furosemide on suramin pharmacokineticsS C Piscitelli, A Forrest, R M Lush, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000

A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumorsE C Dees, L R Whitfield, W R Grove, et al.

Journal of Clinical Pharmacology|March 1, 1996

Effect of age and gender on pharmacokinetics of atorvastatin in humansD M Gibson, N J Bron, A Richens, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1992

A high-performance liquid chromatographic assay for CI-973, a new anticancer platinum diamine complex, in human plasma and urine ultrafiltratesW W Bullen, L D Andress, T Chang, et al.

Pageof 4